TP53 and renal cell carcinoma: This binding could either affect the conformation of TGase 2 dimerization as an active cross-linking enzyme, see Figure S2, or interrupt binding of p53 to TGase 2, see Figure 2F. Finally, we used a xenograft model to demonstrate the potential therapeutic effects of streptonigrin against TGase 2 in RCC.